Bruker Corporation is a leading global provider of scientific instruments and analytical solutions, catering primarily to the life sciences, materials research, and industrial sectors. The company specializes in advanced technologies that facilitate research and development, including mass spectrometry, nuclear magnetic resonance, infrared spectroscopy, and X-ray diffraction. Bruker’s innovative products are essential for a wide range of applications, from drug discovery and environmental monitoring to quality control and materials characterization. Committed to enhancing scientific research and diagnostic capabilities, Bruker supports researchers and industries by delivering precise and reliable data for improved decision-making and insights. Read More
Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...
Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research.
At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius® system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - enhancing laboratory efficiency and supporting higher-throughput volume testing needs.
At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges.
What Happened? Shares of scientific instrument company Bruker (NASDAQ:BRKR). jumped 4% in the afternoon session after the company announced new Nuclear Magne...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue to shrink and systems become increasingly more complex. As the largest supplier of nanoscale infrared (nanoIR) spectroscopy technology to the semiconductor industry, Bruker is expanding the use of AFM-IR beyond its established role in nanoscale contamination analysis into research areas that underpin next-generation semiconductor technologies. These include EUV photoresist patterning and development, advanced materials for transistor scaling, and site-selective surface functionalization at the nanoscale for emerging sensing and functional device applications.
Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience.
PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review (IPR) proceeding IPR2024‑01473 before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women’s Hospital, and exclusively licensed to Seer, Inc.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
What Happened? Shares of scientific instrument company Bruker (NASDAQ:BRKR). jumped 4% in the afternoon session after the company showcased novel analytical ...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Over the past six months, Bruker has been a great trade, beating the S&P 500 by 16%. Its stock price has climbed to $41.37, representing a healthy 23.2% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical applications.
Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications.
Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities, and demonstrate a strong innovation roadmap that extends its technical leadership in each spatial platform, and further integrates multiomics across platforms to accelerate scientific insights — from discovery through translational research.
Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape™, OmniScape™, and GlycoScape™ software now support database-independent PTM discovery, confident proteoform characterization, and eXd-enabled glycoproteomics for deeper biological, disease and drug discovery insights.
Bruker’s fourth quarter results were marked by ongoing weakness in U.S. academic and government funding, tariff-related cost pressures, and unfavorable currency movements. CEO Frank Laukien acknowledged, "2025 was indeed a challenging year for Bruker. We faced multiple unexpected significant headwinds, and we responded by continuing to innovate, launching novel and differentiated high-value solutions." Cost efficiency initiatives helped partially offset margin declines, but these measures could not fully counterbalance the impact of lower volumes and adverse mix.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
